|
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
| Capitalization1 |
196 548 | 197 469 | 214 715 | 217 041 | 217 041 | - |
| Entreprise Value (EV)1 |
215 548 | 213 669 | 230 615 | 237 013 | 232 165 | 226 277 |
| P/E ratio |
25,7x | 15,7x | 30,4x | 26,0x | 20,2x | 18,3x |
| Yield |
3,51% | 3,34% | 3,19% | 3,31% | 3,45% | 3,57% |
| Capitalization / Revenue |
4,00x | 3,80x | 4,53x | 4,41x | 4,12x | 3,95x |
| EV / Revenue |
4,39x | 4,12x | 4,86x | 4,82x | 4,41x | 4,11x |
| EV / EBITDA |
14,9x | 13,7x | 14,6x | 14,5x | 12,6x | 11,6x |
| Price to Book |
2,64x | 2,51x | 3,87x | 3,86x | 3,67x | 3,46x |
| Nbr of stocks (in thousands) |
2 327 340 | 2 309 973 | 2 264 608 | 2 274 506 | 2 274 506 | - |
| Reference price (USD) |
84,5 | 85,5 | 94,8 | 95,4 | 95,4 | 95,4 |
| Last update |
01/24/2018 | 01/30/2019 | 01/29/2020 | 01/18/2021 | 01/18/2021 | 01/18/2021 |
|
1 USD in Million Estimates
|
|
| Income Statement Evolution | |
|
|
|
| Annual Income Statement Data |
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
| Net sales1 |
49 109 | 51 900 | 47 445 | 49 178 | 52 652 | 55 002 |
| EBITDA1 |
14 492 | 15 646 | 15 809 | 16 306 | 18 425 | 19 561 |
| Operating profit (EBIT)1 |
12 850 | 13 823 | 14 112 | 15 446 | 17 044 | 18 285 |
| Operating Margin |
26,2% | 26,6% | 29,7% | 31,4% | 32,4% | 33,2% |
| Pre-Tax Profit (EBT)1 |
8 999 | 13 835 | 8 940 | 9 995 | 12 865 | 14 022 |
| Net income1 |
7 703 | 12 611 | 7 147 | 8 251 | 10 411 | 11 348 |
| Net margin |
15,7% | 24,3% | 15,1% | 16,8% | 19,8% | 20,6% |
| EPS2 |
3,28 | 5,44 | 3,12 | 3,67 | 4,73 | 5,20 |
| Dividend per Share2 |
2,97 | 2,85 | 3,02 | 3,15 | 3,29 | 3,40 |
| Last update |
01/24/2018 | 01/30/2019 | 01/29/2020 | 01/18/2021 | 01/18/2021 | 01/18/2021 |
|
1 USD in Million 2 USD Estimates
|
|
|
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
| Net Debt1 |
19 000 | 16 200 | 15 900 | 19 972 | 15 125 | 9 236 |
| Net Cash position1 |
- | - | - | - | - | - |
| Leverage (Debt / EBITDA) |
1,31x | 1,04x | 1,01x | 1,22x | 0,82x | 0,47x |
| Free Cash Flow1 |
10 428 | 11 717 | 12 875 | 13 008 | 14 744 | 16 531 |
| ROE (Net Profit / Equities) |
15,3% | 16,5% | 17,5% | 22,7% | 24,6% | 25,3% |
| Shareholders' equity1 |
50 380 | 76 391 | 40 842 | 36 398 | 42 282 | 44 825 |
| ROA (Net Profit / Asset) |
5,85% | 9,05% | 8,89% | 7,83% | 9,18% | 9,66% |
| Assets1 |
131 601 | 139 321 | 80 393 | 105 427 | 113 433 | 117 514 |
| Book Value Per Share2 |
32,0 | 34,0 | 24,5 | 24,7 | 26,0 | 27,5 |
| Cash Flow per Share2 |
5,37 | 5,38 | 5,88 | 5,76 | 6,74 | 7,40 |
| Capex1 |
1 696 | 1 773 | 2 257 | 1 551 | 1 738 | 1 760 |
| Capex / Sales |
3,45% | 3,42% | 4,76% | 3,15% | 3,30% | 3,20% |
| Last update |
01/24/2018 | 01/30/2019 | 01/29/2020 | 01/18/2021 | 01/18/2021 | 01/18/2021 |
|
1 USD in Million 2 USD Estimates
|
|
|
|
|
|
Financial data source
© 2021 S&P Global Market Intelligence
|
|
|
Novartis : buys neuroscience company Cadent for up to $770 million |
|
NOVARTIS AG
Back to basics |
Capitalization (CHF) 193 401 265 247 Capitalization (USD) 217 177 901 953 Net sales (USD) 47 445 000 000 Number of employees 110 000 Sales / Employee (USD) 431 318 Free-Float capitalization (CHF) 167 014 070 420 Free-Float capitalization (USD) 187 546 681 063 Avg. Exchange 20 sessions (USD) 392 901 803 Average Daily Capital Traded 0,20%
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Evolution Valeur d'Entreprise / EBITDA
|
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
